IDERA PHARMACEUTICALS Aktie

0,83 EUR -1,8935%

Zu Ihrem Onlinebroker

kaufen verkaufen

IDERA PHARMACEUTICALS Aktienkurs : 25.05. ( 15 Min. verzögert)
0,829 € Letzter Kurs	-1,89% Veränderung	0,845 € Vortag	0,816 € Eröffnungskurs

Realtime:

0,83

-1,89%

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
0,829 - 0,816 Tag	1,77 - 0,727 52 Wochen	0 Tag	288 Ø 52 Wochen	0,795 4.090 Stücke	0,826 3.640 Stücke

IDERA PHARMACEUTICALS Aktienk…

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

10.05.

Biogen Announces US and EU Authorities Accept Oral BG-12 Marketing ...

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial results for the quarter ended March 31, 2012. Human Genome Sciences, Inc. (Nasdaq: HGSI) today confirmed that GlaxoSmithKline plc (…
09.05.

Idera Pharmaceuticals Reports First Quarter 2012 Financial Results

CAMBRIDGE, Mass., May 09, 2012 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) today reported financial results for the quarter ended March 31, 2012. "We are focusing our development effort on...

07.05.

How To Avoid Life Sciences Partnership Pitfalls

... rationale, first it's really important for pharmas to decide whether they want to be in the space,” Sudhir Agrawal, chairman of Idera Pharmaceuticals, says. Idera began developing compounds targeting toll-like receptors (TLRs) ...
07.05.

Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical ...

CAMBRIDGE, Mass., May 07, 2012 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable...
04.05.

Idera Pharmaceuticals Announces Top-line Results from a Phase 2 Clinical Trial ...

(EON: Enhanced Online News)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced top-line results of a randomized, controlled Phase 2 clinical trial of IMO-2055, the Company's investigational...